The global pharmaceutical industry is shifting to emerging markets, and multinationals are moving eastward, and China’s custom synthesis CRO industry is widely favored because of its advantages such as talent and resource adequacy. According to reliable reports, China has gradually surpassed India as Asia’s first outsourcing industry base in customizing the CRO. Some experts assert that hard work among the global custom synthesis CRO first array is only a matter of time, but in many ways, Chinese local CRO enterprises need to continue to improve and strengthen.

In this context, as far as global CRO takes on nearly 1/3 of the world’s new drug development work, and the CRO market increases by 20% per cent a year, more than 300 of China’s CRO companies account for 5% of the global outsourcing market, attracting VCs and big Cro to accelerate the pace of the Chinese market. Many local CRO companies have realised that industry shuffling is accelerating.

China’s policies are also helping to create the CRO market. The Ministry of Health and in June announced a major new drug creation “Twelve-Five” program task has been launched in batches. This is a great help to the development of China’s custom synthesis CRO market, and it has a long history of influence.
The Ministry of Health said in the relevant announcements, major new drug creation is the national 2006 to 2020 medium and long-term development planning of 16 major projects. The state plans to invest a total of $35 billion in the “Eleven-Five” to “Thirteen-Five” period, of which the “Eleven-Five” period has already invested 6.6 billion yuan.
The relative strategic deployment of the country makes the development of innovative drugs a water-duck, but also means that a copycat, imitation-oriented CRO Enterprise is facing crisis and challenge. At this stage, foreign investment is gradually entering the Chinese market, so in the foreseeable future, the local custom synthetic CRO will gradually mature and become integrated with the global CRO market.
Custom SynthesisNews
The global pharmaceutical industry is shifting to emerging markets, and multinationals are moving eastward, and China's custom synthesis CRO industry is widely favored because of its advantages such as talent and resource adequacy. According to reliable reports, China has gradually surpassed India as Asia's first outsourcing industry base in...